Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression.
Skyhawk Therapeutics has raised $133.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2021.
Skyhawk Therapeutics's investors include GreatPoint Ventures, Fidelity, Rock Springs Capital, Good Growth Capital, Agent Capital.
Skyhawk Therapeutics is headquartered in Waltham, United States.
Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression.
Skyhawk Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Skyhawk Therapeutics — Funding & Investors." VCBacked, September 14, 2021, https://www.vcbacked.co/company/skyhawk-therapeutics. Accessed November 12, 2026.
VCBacked. (2021). Skyhawk Therapeutics — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/skyhawk-therapeutics
{{cite web |title=Skyhawk Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/skyhawk-therapeutics |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Skyhawk Therapeutics? Request a listing update